Glucotrack, INC 8-K filings

Glucotrack, Inc. adjourned its special meeting of stockholders due to insufficient attendance, postponing a vote on an 'Issuance Proposal' to November 7, 2025.

Glucotrack, Inc. reconvenes its Special Meeting on November 7, 2025, urging shareholders to vote on a $20 million Equity Purchase Agreement with Sixth Borough Capital Fund LP.

Glucotrack, Inc. announced the appointment of Dr. Usman Latif, a neuromodulation and painful diabetic neuropathy expert, to its clinical advisory team to advance integrated glucose monitoring applications.

Glucotrack, Inc. reminds shareholders to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund at a Special Meeting on October 31, 2025.

Glucotrack, Inc. has issued a $3.6 million principal convertible promissory note for $3 million cash, bearing zero interest and convertible upon a qualified financing.

Glucotrack, Inc. entered into a purchase agreement with Sixth Borough Capital Fund, LP for up to $20 million in common stock, providing flexible capital over 24 months.

Glucotrack reports Q2 2025 financial results, highlights significant clinical progress, and improved capital structure, extending cash runway through 2025.

Glucotrack, Inc. announced the appointment of David S. Hirsh, MD, as Medical Director, Cardiology, to advance its continuous blood glucose monitor through clinical milestones.

Glucotrack, Inc. announced its participation in the 2025 ADCES Annual Meeting to showcase its implantable Continuous Blood Glucose Monitor (CBGM) and present physician perspectives on the technology, as it advances toward a US pilot study.

Glucotrack, Inc. filed an amendment to its 8-K report to include a letter from its former auditor, Grant Thornton, confirming agreement with the company's statements regarding the change in accounting firm.

Glucotrack, Inc. has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm, replacing Grant Thornton, which had previously raised substantial doubt about the company's ability to continue as a going concern and noted material weaknesses in internal controls.

Glucotrack, Inc. announced the successful repurchase of over 90% of its outstanding Series A Warrants, aiming to strengthen its capital structure and reduce potential share dilution.

Glucotrack, Inc. announced positive final results from its first-in-human clinical study for its implantable Continuous Blood Glucose Monitor, demonstrating strong accuracy with a 7.7% MARD and excellent safety.

Glucotrack, Inc. has completed a 1-for-60 reverse stock split, effective June 13, 2025, significantly reducing its outstanding shares and adjusting per-share financial metrics.

Glucotrack, Inc. has announced a 1-for-60 reverse stock split, effective June 16, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement and attracting institutional investors.

Glucotrack, Inc. announced it will present safety and performance data from its first-in-human trial of its implantable continuous blood glucose monitoring system at the American Diabetes Association's 85th Scientific Sessions.

Glucotrack, Inc. announced that its stockholders approved a reverse stock split, an increase in shares for its equity incentive plan, and the election of directors at its 2025 annual meeting.

GlucoTrack, Inc. forms a Patient Advisory Board to incorporate patient insights into the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM).

Glucotrack announces its Q1 2025 financial results, highlighting progress in its CBGM development and upcoming clinical trials.

Glucotrack, Inc. has received ethical approval for a long-term clinical study of its continuous blood glucose monitor (CBGM) in participants with type 1 and type 2 diabetes.

GlucoTrack, Inc. issued an investor presentation on April 29, 2025.

Glucotrack, Inc. will participate in the FORGETDIABETES initiative, a European research program focused on developing a bionic pancreas for automated insulin delivery.

GlucoTrack, Inc. received a delisting notice from Nasdaq due to its common stock price falling below the required $1.00 per share minimum.

GlucoTrack, Inc. announces a strategic agreement with OneTwo Analytics AB to leverage AI-driven analytics for its Continuous Blood Glucose Monitor (CBGM) clinical study data.

Glucotrack, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting its transition to a clinical-stage company and advancements in its continuous blood glucose monitoring (CBGM) technology.

Glucotrack, Inc. announces the presentation of safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes.

GlucoTrack, Inc. announces the conversion of debt and warrants into common stock, issuing shares to note investors and warrant holders.

Glucotrack, Inc. announces the appointment of Dr. Guillermo Umpierrez to its Medical Advisory Board as the company advances its long-term implantable blood glucose monitoring technology.

GlucoTrack, Inc. distributed a slide presentation as a shareholder update on February 14, 2025.

Glucotrack, Inc. has announced the pricing of a $3.0 million public offering of common stock at $1.15 per share.